Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.

Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD.

Cancer Immunol Res. 2019 Sep;7(9):1412-1425. doi: 10.1158/2326-6066.CIR-19-0258. Epub 2019 Jul 23.

PMID:
31337659
2.

False-positive screening events and worry influence decisions about surgery among high-risk women.

Andersen MR, Karlan BY, Drescher CW, Paley P, Hawley S, Palomares M, Daly MB, Urban N.

Health Psychol. 2019 Jan;38(1):43-52. doi: 10.1037/hea0000647. Epub 2018 Nov 15.

PMID:
30431292
3.

The Yet Unrealized Promise of Ovarian Cancer Screening.

Drescher CW, Anderson GL.

JAMA Oncol. 2018 Apr 1;4(4):456-457. doi: 10.1001/jamaoncol.2018.0028. No abstract available.

PMID:
29450480
4.

Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells.

Cai X, Caballero-Benitez A, Gewe MM, Jenkins IC, Drescher CW, Strong RK, Spies T, Groh V.

Neoplasia. 2017 Jun;19(6):471-482. doi: 10.1016/j.neo.2017.03.005. Epub 2017 May 9.

5.

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH.

Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.

6.

The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.

Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.

Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.

7.

Extracting a low-dimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer.

Celik S, Logsdon BA, Battle S, Drescher CW, Rendi M, Hawkins RD, Lee SI.

Genome Med. 2016 Jun 10;8(1):66. doi: 10.1186/s13073-016-0319-7.

8.

Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.

Buas MF, Gu H, Djukovic D, Zhu J, Drescher CW, Urban N, Raftery D, Li CI.

Gynecol Oncol. 2016 Jan;140(1):138-44. doi: 10.1016/j.ygyno.2015.10.021. Epub 2015 Oct 30.

9.

Targeted single molecule mutation detection with massively parallel sequencing.

Gregory MT, Bertout JA, Ericson NG, Taylor SD, Mukherjee R, Robins HS, Drescher CW, Bielas JH.

Nucleic Acids Res. 2016 Feb 18;44(3):e22. doi: 10.1093/nar/gkv915. Epub 2015 Sep 17.

10.

Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.

Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, Anderson GL.

Gynecol Oncol. 2015 Nov;139(2):253-60. doi: 10.1016/j.ygyno.2015.08.024. Epub 2015 Sep 3.

11.

Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1.

12.

Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Lutz AM, Bachawal SV, Drescher CW, Pysz MA, Willmann JK, Gambhir SS.

Clin Cancer Res. 2014 Mar 1;20(5):1313-22. doi: 10.1158/1078-0432.CCR-13-1642. Epub 2014 Jan 3.

13.

Digital genomic quantification of tumor-infiltrating lymphocytes.

Robins HS, Ericson NG, Guenthoer J, O'Briant KC, Tewari M, Drescher CW, Bielas JH.

Sci Transl Med. 2013 Dec 4;5(214):214ra169. doi: 10.1126/scitranslmed.3007247.

14.

High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer.

Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J, Williamson DW, Carlson CS, Drescher CW, Tewari M, Bielas JH, Robins HS.

J Pathol. 2013 Dec;231(4):433-440. doi: 10.1002/path.4260.

15.

Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer.

Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA.

J Altern Complement Med. 2013 Aug;19(8):714-20. doi: 10.1089/acm.2012.0295. Epub 2013 Feb 27.

16.

Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW.

J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17.

17.

Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7.

18.

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK.

Gynecol Oncol. 2012 Dec;127(3):538-43. doi: 10.1016/j.ygyno.2012.08.020. Epub 2012 Aug 23. Erratum in: Gynecol Oncol. 2013 Jul;130(1):252-3.

19.

Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening.

Drescher CW, Hawley S, Thorpe JD, Marticke S, McIntosh M, Gambhir SS, Urban N.

Cancer Prev Res (Phila). 2012 Aug;5(8):1015-24. doi: 10.1158/1940-6207.CAPR-11-0468. Epub 2012 Jul 2.

20.

Involvement in decision-making about treatment and ovarian cancer survivor quality of life.

Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA.

Gynecol Oncol. 2012 Mar;124(3):465-70. doi: 10.1016/j.ygyno.2011.10.029. Epub 2011 Oct 29.

21.

ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.

Salzman J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, Drescher CW, Brown PO.

PLoS Biol. 2011 Sep;9(9):e1001156. doi: 10.1371/journal.pbio.1001156. Epub 2011 Sep 20.

22.

An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.

Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, Drescher CW, Swisher EM, Tewari M.

Nucleic Acids Res. 2012 Jan;40(2):499-510. doi: 10.1093/nar/gkr731. Epub 2011 Sep 14.

23.

Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW.

J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4. doi: 10.1093/jnci/djr359. Epub 2011 Sep 14.

24.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

25.

Early diagnosis of ovarian carcinoma: is a solution in sight?

Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, Gambhir SS.

Radiology. 2011 May;259(2):329-45. doi: 10.1148/radiol.11090563. Review.

PMID:
21502390
26.

Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases.

Paley PJ, Veljovich DS, Shah CA, Everett EN, Bondurant AE, Drescher CW, Peters WA 3rd.

Am J Obstet Gynecol. 2011 Jun;204(6):551.e1-9. doi: 10.1016/j.ajog.2011.01.059. Epub 2011 Mar 16.

PMID:
21411053
27.

DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.

Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, Laird PW.

PLoS One. 2010 Feb 22;5(2):e9359. doi: 10.1371/journal.pone.0009359.

28.

Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N.

Gynecol Oncol. 2010 Mar;116(3):378-83. doi: 10.1016/j.ygyno.2009.10.087. Epub 2009 Nov 28.

29.

Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.

Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M.

Gynecol Oncol. 2010 Jan;116(1):117-25. doi: 10.1016/j.ygyno.2009.08.009. Epub 2009 Oct 24.

30.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

31.

Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.

Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B.

OMICS. 2009 Aug;13(4):345-54. doi: 10.1089/omi.2009.0008.

32.

Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.

Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M.

PLoS One. 2009;4(4):e5311. doi: 10.1371/journal.pone.0005311. Epub 2009 Apr 23.

33.

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK.

Gynecol Oncol. 2009 Apr;113(1):21-7. doi: 10.1016/j.ygyno.2008.12.003. Epub 2009 Jan 21.

34.

Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7. doi: 10.1158/1055-9965.EPI-08-0150.

35.

Circulating microRNAs as stable blood-based markers for cancer detection.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.

36.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

37.

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM.

PLoS One. 2008 Jun 18;3(6):e2425. doi: 10.1371/journal.pone.0002425.

38.

Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging.

Veljovich DS, Paley PJ, Drescher CW, Everett EN, Shah C, Peters WA 3rd.

Am J Obstet Gynecol. 2008 Jun;198(6):679.e1-9; discussion 679.e9-10. doi: 10.1016/j.ajog.2008.03.032.

PMID:
18538151
39.

Changes in cancer worry associated with participation in ovarian cancer screening.

Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, McIntosh M, Mahony BS, Lowe KA, Urban N.

Psychooncology. 2007 Sep;16(9):814-20.

PMID:
17225260
40.

Development of an ovarian cancer symptom index: possibilities for earlier detection.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR.

Cancer. 2007 Jan 15;109(2):221-7.

41.

Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis.

Shah C, Pizer E, Veljovich DS, Drescher CW, Peters WA 3rd, Paley PJ.

Gynecol Oncol. 2006 Dec;103(3):1130-2. Epub 2006 Sep 22.

PMID:
16996119
42.

Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.

43.

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML.

J Clin Oncol. 2006 Feb 10;24(5):762-8. Epub 2006 Jan 3.

PMID:
16391298
44.

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B.

Mol Cell Proteomics. 2006 Mar;5(3):433-43. Epub 2005 Nov 30. Erratum in: Mol Cell Proteomics. 2006 Jun;5(6):1171.

45.

Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N.

Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6.

46.

Adequate staging for uterine cancer can be performed through Pfannenstiel incisions.

Horowitz NS, Powell MA, Drescher CW, Smith MR, Atwood M, Mate TA, Peters WA.

Gynecol Oncol. 2003 Mar;88(3):404-10.

PMID:
12648594
47.

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, Micha JP.

Gynecol Oncol. 2003 Feb;88(2):136-40.

PMID:
12586592
48.

Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.

Horowitz NS, Peters WA 3rd, Smith MR, Drescher CW, Atwood M, Mate TP.

Obstet Gynecol. 2002 Feb;99(2):235-40.

PMID:
11814503
49.

Rectal prolapse in women with other defects of pelvic floor support.

Peters WA 3rd, Smith MR, Drescher CW.

Am J Obstet Gynecol. 2001 Jun;184(7):1488-94; discussion 1494-5.

PMID:
11408872
50.

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP.

Gynecol Oncol. 2000 Dec;79(3):495-8.

PMID:
11104627

Supplemental Content

Loading ...
Support Center